title: [An experience of OK-432 intradermal administration in superficial bladder tumors].
abstract: A streptococcal preparation, OK432 was evaluated as the adjuvant immunotherapeutic agent for superficial bladder tumors. Twenty-nine cases were treated with complete transurethral resection and then randomized prospectively into two groups. One group had adjuvant therapy of OK432 intradermal administration and another group had no adjuvant therapy. OK432 administration significantly reduced the recurrence rates as compared to the control group. Although further studies were required for its full significance, in a short-term study, OK432 intradermal administration produced a beneficial effect in reducing the recurrence rates.
authors.affiliation: Department of Urology, Kinki University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Tsujihashi
authors.forename: T
authors.initials: T
authors.lastname: Akiyama
authors.forename: T
authors.initials: T
authors.lastname: Kurita
authors.forename: M
authors.initials: M
authors.lastname: Iguchi
authors.forename: S
authors.initials: S
authors.lastname: Uejima
authors.forename: K
authors.initials: K
authors.lastname: Kataoka
authors.forename: S
authors.initials: S
authors.lastname: Minakata
authors.forename: M
authors.initials: M
authors.lastname: Kitagawa
authors.forename: H
authors.initials: H
authors.lastname: Sangen
mesh_terms: D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
chemical_list: D001688:Biological Products; D010844:Picibanil